Revivicor Inc., a leader in xenotransplantation research under United Therapeutics, has found an unexpected application for its genetically modified pigs beyond organ transplantation. These “GalSafe” pigs, altered to eliminate the alpha-gal sugar responsible for allergic reactions in humans, are providing free pork products to individuals suffering from alpha-gal syndrome.
The syndrome, triggered by the consumption of mammalian meats and products, causes severe allergic reactions. Revivicor’s pigs, approved by the FDA in 2020, have been bred specifically to be alpha-gal-free, ensuring safe consumption for allergy patients. While primarily a research endeavor, Revivicor supplies these specially processed pork products to applicants across the country, offering relief and joy to those previously deprived of enjoying meats like bacon and ribs.
Despite their unique role in addressing allergies, Revivicor emphasizes that these pigs are not intended for commercial food production due to regulatory considerations. Instead, the company remains focused on advancing xenotransplantation, with ongoing experiments including a recent kidney transplant at NYU Langone Health using a genetically modified GalSafe pig.
The dual-purpose use of these pigs highlights their potential to revolutionize both allergy treatment and future organ transplantation efforts, marking a significant step forward in medical research and patient care.